ADMELOG
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADMELOG (ADMELOG).
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor, activating downstream signaling pathways to facilitate cellular glucose uptake, inhibit hepatic gluconeogenesis, and promote glycogen synthesis, lipogenesis, and protein synthesis.
| Metabolism | Insulin lispro is primarily metabolized by insulin-degrading enzyme (IDE) in the liver, kidneys, and muscle tissue, with minimal hepatic first-pass effect. |
| Excretion | Renal (primarily as unchanged drug, following degradation by insulin-degrading enzyme). Approximately 60-80% of a dose is excreted renally; the remainder is metabolized in the liver and kidneys. |
| Half-life | Terminal elimination half-life is approximately 1.5-2.5 hours (subcutaneous administration). This short half-life reflects rapid absorption and clearance, suitable for prandial glucose control. |
| Protein binding | Very low (<5%), mostly to albumin and other plasma proteins. Clinical relevance: minimal binding allows rapid free drug availability. |
| Volume of Distribution | 0.2-0.4 L/kg (approximately 10-15 L in adults). This Vd approximates extracellular fluid volume, indicating limited tissue penetration. |
| Bioavailability | Subcutaneous: 55-65% (due to local degradation). Intravenous: 100%. |
| Onset of Action | Subcutaneous: 15-30 minutes. Intravenous: 5-15 minutes. |
| Duration of Action | Subcutaneous: 3-5 hours (duration of glucose-lowering effect). Clinical note: Duration is dose-dependent and may be shorter at lower doses; acts as a bolus insulin for meal-time coverage. |
Subcutaneous injection: 0.2-1.0 units/kg/day divided into 2-4 doses. Typical starting dose: 0.4-0.6 units/kg/day. Administer within 15 minutes before or immediately after a meal.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment required for mild to moderate renal impairment. In severe renal impairment (eGFR <30 mL/min), reduce dose by 25-50% and monitor glucose closely due to increased risk of hypoglycemia. |
| Liver impairment | No specific dose adjustment for mild hepatic impairment (Child-Pugh A). In moderate to severe hepatic impairment (Child-Pugh B or C), reduce starting dose by 25-50% and titrate cautiously due to altered glucose metabolism and increased hypoglycemia risk. |
| Pediatric use | For type 1 diabetes: initial total daily dose 0.2-0.5 units/kg/day, divided into 2-4 doses. For type 2 diabetes: 0.2-0.5 units/kg/day, divided into 2-4 doses; titrate based on blood glucose levels. Not recommended for children <6 years in some guidelines; efficacy and safety established for age ≥6 years. |
| Geriatric use | Start with lower doses (e.g., 0.2-0.4 units/kg/day) due to increased risk of hypoglycemia and reduced renal function. Titrate slowly and monitor blood glucose more frequently. Consider lower initial doses in patients with renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ADMELOG (ADMELOG).
| Breastfeeding | Insulin glargine is a large protein molecule that is minimally excreted into breast milk and is unlikely to affect the nursing infant. M/P ratio is not established. Considered compatible with breastfeeding; monitor infant for hypoglycemia. |
| Teratogenic Risk | Insulin glargine (ADMELOG) does not cross the placenta in significant amounts; no teratogenic effects have been observed in animal studies. Limited human data show no increased risk of major congenital anomalies. However, uncontrolled maternal diabetes increases fetal risk for malformations, macrosomia, and neonatal complications. Insulin requirements may change during pregnancy. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to insulin lispro or any excipients","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia is the most common adverse effect; monitoring blood glucose is essential.","Changes in insulin strength, manufacturer, type, or method of administration may require dose adjustment.","Concomitant use with thiazolidinediones may increase risk of fluid retention and heart failure.","Risk of severe hypoglycemia in patients with renal or hepatic impairment.","Hypersensitivity reactions may occur."] |
| Food/Dietary | No known food interactions. However, timing of insulin must be synchronized with carbohydrate intake to prevent hypoglycemia or hyperglycemia. Avoid alcohol, which can increase risk of hypoglycemia. High-fat meals may delay absorption and blood glucose lowering effect. |
Loading safety data…
| Fetal Monitoring | Monitor blood glucose levels frequently (including HbA1c) in mother. Perform fetal ultrasound for anatomy and growth assessment. Monitor for fetal macrosomia, polyhydramnios, and neonatal hypoglycemia. Adjust insulin doses as needed. |
| Fertility Effects | No known direct adverse effects on fertility. Uncontrolled diabetes may impair fertility through hormonal imbalances; achieving glycemic control with insulin may improve fertility. |
| Clinical Pearls | ADMELOG (insulin lispro) is a rapid-acting insulin analogue. Onset within 15 minutes, peak at 30-90 minutes, duration 3-5 hours. Administer within 15 minutes of meal or immediately after. Do not mix with NPH insulin in same syringe if cloudy; if mixing, draw clear lispro first. Monitor for hypoglycemia, especially during dose titration. Use with caution in renal or hepatic impairment. |
| Patient Advice | Inject within 15 minutes before or immediately after a meal. · Do not use if solution is cloudy or thickened; only clear solution is safe. · Rotate injection sites to prevent lipodystrophy. · Carry a source of fast-acting sugar (e.g., glucose tablets) for hypoglycemia. · Do not mix with other insulins without consulting your healthcare provider. · Store unopened vials in refrigerator; opened vials at room temperature for up to 28 days. · Never share pens or needles with others. |